FDA advisory committee to review Novavax’s COVID-19 vaccine candidate in June


Shares of Novavax Inc. NVAX, +1.81% jumped 10.8% in trading on Friday after the Food and Drug Administration announced that an advisory committee is set to meet June 7 to examine the benefits and risks of the company’s experimental COVID-19 vaccine. Novavax’s protein-based vaccine has been authorized in several countries, including by the U.K. and the European Commission, but is still being reviewed by the FDA. The company’s stock has tumbled 65.6% this year, while the broader S&P 500 SPX, -3.63% is down 10.0%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous article: Lyft vows to pay legal fees for drivers who might be sued under expected Oklahoma abortion law
Next articleU.S. consumer sentiment has jumped in April: University of Michigan


Please enter your comment!
Please enter your name here